International Paper Company Common Stock vs Medpace Holdings Inc — how do they compare? International Paper Company Common Stock trades at $32.03 (market cap $16.85B), while Medpace Holdings Inc trades at $616.98 (market cap $17.02B). The key difference: International Paper Company Common Stock and Medpace Holdings Inc are close in size by market cap, and International Paper Company Common Stock pays a 5.82% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold International Paper Company Common Stock for 0 Days and Medpace Holdings Inc for 14 Days on average.
| IP | MEDP | |
|---|---|---|
Market Cap | $16.85B | $17.02B |
Volume | 3,482,586 | 155,250 |
Sector | Basic Materials | Health |
52-Week High | $49.19 | $630.19 |
52-Week Low | $29.38 | $393.42 |
Typical Hold Time | 0 Days | 14 Days |
Enterprise Value | $25.81B | $16.63B |
Dividend Yield | 5.82% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MEDP trades at $609.89, down 1.64% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent news highlights CEO stock sales and institutional position adjustments, while Q3 2026 results are expected October 21, 2026.
MEDP offers growth potential with a consensus price target of $620.44 (1.7% upside), supported by projected 2026 revenue growth to $2.8B. Risks include high valuation multiples (P/E 35.82) and insider selling. Analyst sentiment is cautious with 78.95% hold ratings, suggesting limited near-term catalysts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
International Paper Company is a US producer of fiber-based packaging, pulp, and paper products, manufacturing corrugated packaging and containerboard used to ship and protect goods.
Read more on IP →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →